



Miltenyi Biotec

TheraSorb® – Ig omni 1 adsorber

Effective removal of IgG, IgM, IgA, and IgE

TheraSorb – Ig omni 1 adsorber is Miltenyi Biotec's first single-use adsorber in a new generation of columns containing recombinant antibody fragments as ligands.

- Single-use adsorber
- Low risk of reaction to foreign proteins¹
- Removal of free lambda and kappa light chains¹

► miltenyibiotec.com



TheraSorb – Ig omni 1 adsorber

The TheraSorb – Ig omni 1 adsorber has been carefully designed for the specific removal of human immunoglobulins containing lambda and kappa chains, including IgG (subclasses IgG1–IgG4), IgA, IgM, IgE, and immune complexes as well as free lambda and kappa light chains from human plasma in extracorporeal immunoadsorption procedures, as the plasma flows through the column.

Areas of application

The TheraSorb – Ig omni 1 adsorber is intended to be used for immunoadsorption treatment of diseases in which pathogenic immunoglobulins, lambda or kappa light chains, and immune complexes, contribute to the onset of the disease or its progression. A positive benefit-risk ratio has been shown by clinical trials or case series in conjunction with other modes of treatment in the following exemplary indications:

- idiopathic dilated cardiomyopathy NYHA II – IV²
- ABO blood group incompatible living donor kidney transplantation^{3,4}
- acquired hemophilia with an inhibitor titer to factor VIII of more than 5 Bethesda Units⁵
- pulmonary arterial hypertension NYHA II – III⁶
- thrombangiitis obliterans (Buerger's disease)⁷
- myasthenia gravis/myasthenic crisis⁸
- focal segmental glomerulosclerosis, recurrent and idiopathic form⁹
- severe systemic lupus erythematosus¹⁰
- antiphospholipid syndrome in pregnancy¹¹
- severe atopic dermatitis¹²
- antibody-mediated rejection after kidney transplantation¹³
- long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)¹⁴

This adsorber is specific for the removal of human immunoglobulin and free antibody light chains from the patient's plasma. Over 70% of circulating IgG can be removed in one session using the TheraSorb – Ig omni 1 adsorber (fig. 1)¹.

Product specifications

Shelf life	36 months*
Sepharose volume	45 mL
Immunological target	IgG, IgM, IgA, and IgE, free lambda and kappa light chains

*Please note: Adsorber can be stored at room temperature.

Product	Order no.
TheraSorb – Ig omni 1 adsorber kit	330-000-964
Ig omni 1 complete treatment set LIFE 21	330-000-825
LIFE 21 – Ig omni 1 disposables set large	330-000-841
LIFE 21 – Ig omni 1 disposables set small	330-000-842




Figure 1: Remaining IgG concentration in patient plasma after *in vitro* immunoadsorption using the TheraSorb – Ig omni 1 adsorber. Immunoadsorption using different settings on the LIFE 21® apheresis unit shows a gradual decrease in plasma IgG levels with an increasing volume of treated patient plasma. Legend indicates software mode of the LIFE 21 apheresis unit and the initial IgG concentration.

References

1. Internal data
2. Dandel, M. *et al.* (2012) *Eur. J. Heart Fail.* 14: 1374–1388.
3. Teschner, S. *et al.* (2012) *J. Clin. Apher.* 27: 51–60.
4. Becker, L.E. *et al.* (2015) *Transplantation* 99: 2364–2371.
5. Zeitler, H. *et al.* (2012) *Transfusion Med. Hemother.* 39: 264–270.
6. Nagel, C. *et al.* (2017) *Respiration* 94: 263–271.
7. Baumann, G. *et al.* (2011) *Clin. Res. Cardiol.* 100: 683–690.
8. Zeitler, H. *et al.* (2006) *Artif. Organs* 30: 597–605.
9. Allard, L. *et al.* (2018) *Nephrol. Dial. Transplant.* 33: 954–963.
10. Kronbichler, A. *et al.* (2016) *Autoimmunity Rev.* 15: 38–49.
11. Bontadi, A. *et al.* (2012) *J. Clin. Apher.* 27: 200–204.
12. Reich, K. *et al.* (2016) *J. Allergy Clin. Immunol.* 137: 1882–1884.
13. Koller, H. *et al.* *Transpl. Int.* 17: 177–181.
14. Stein, E. *et al.* (2024) *Lancet Reg. Health Eur.* 49: 101161.